Autopsy report · NCT01227941
MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Cause of deathNo reason given
Life of this trial
- Ran for about 10 months before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Tesaro, Inc.
- Sponsor type
- Industry
- Conditions
- Ovarian Cancer
- Interventions
- MK-4827 + pegylated liposomal doxorubicin; MK-4827 + pegylated liposomal doxorubicin
- Participants
- 6
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.